Posts tagged Phase 2b
HCW starts Gemphire at buy

H.C. Wainwright launched coverage of Gemphire Therapeutics (NASDAQ:GEMP) with a “buy” rating and a price target of $21, saying it views the sell off in the shares following results of the ROYAL-1 clinical trial as overdone. The stock closed at $9.17 on August 30.

Read More
Theratechnologies presents new HIV findings

Theratechnologies’ (TSX:TH) presented results on HIV susceptibility to ibalizumab from a Phase 2b trial, along with new findings for EGRIFTA (tesamorelin for injection), at the 9th IAS Conference on HIV Science in Paris.

Read More
HCW starts ObsEva at buy

H.C. Wainwright initiated coverage of Swiss-based ObsEva (NASDAQ:OBSV) with a “buy” rating and $27 price target. The stock closed at $7.50 on June 29.

Read More
Maxim cuts Stellar Bio price target to $2

Maxim Group slashed its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $2 from $4, but maintained its “buy” rating, after the company reported fiscal second quarter results. The stock closed at $1.32 on May 9.

Read More
Roth starts Poxel SA at buy

Roth Capital Partners initiated coverage of Poxel SA (NXT:PA) with a “buy” rating and price target of €11. The stock was recently quoted at €5.14.

Read More
HCW upgrades Galectin to buy

H.C. Wainwright upgraded Galectin Therapeutics (NASDAQ:GALT) to “buy” from “neutral” and raised its price target to $3 from 60 cents, citing a more positive view of the therapeutic potential of the mechanism of galectin-3 inhibition. The stock closed at $1.98 on March 29.

Read More
Analysts raise Aurinia price targets

Analysts for H.C. Wainwright and Leerink raised their price targets for Aurinia Pharmaceuticals (NASDAQ:AUPH) after the company reviewed positive Phase 2b trial data for voclosporin in lupus nephritis (LN), which met its complete and partial remission (CR/PR) endpoints at 48 weeks.

Read More
Aurinia’s voclosporin meets 48-week remission endpoints

Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) Phase 2b AURA-LV study of voclosporin in lupus nephritis (LN) met its complete and partial remission (CR/PR) endpoints at 48 weeks.

Read More
Maxim raises Ritter Pharma price target to $5

Maxim Group raised its price target for Ritter Pharmaceuticals (NASDAQ:RTTR) to $5 from $4 ahead of top-line data in the current quarter for a Phase 2b/3 study of RP-G28 for the treatment of lactose intolerance. The stock closed at $3.49 on Feb. 13.

Read More
Stifel downgrades Ocera Therapeutics to hold

Stifel downgraded Ocera Therapeutics (NASDAQ:OCRX) to “hold” from “buy” and slashed its price target to $1 from $9 after the company reported top-line results from a Phase 2b study evaluating ornithine phenylacetate (OCR-002) in hospitalized patients with hepatic encephalopathy (HE).

Read More
Maxim ups Galena Biopharma price target to $4

Maxim Group raised its price target for Galena Biopharma (NASDAQ:GALE) to $4 from $1, saying the company has multiple programs moving forward, including NeuVax. The stock was quoted at $2.90 in afternoon trading on Dec. 2.

Read More
Oramed GLP-1 analog found safe in study

Oramed Pharmaceuticals (NASDAQ:ORMP) has successfully concluded a Phase 1b study of ORMD-0901, its oral GLP-1 analog, in Type 2 diabetes patients.

Read More
Ladenburg upgrades Repros Therapeutics to buy

Ladenburg Thalmann upgraded Repros Therapeutics (NASDAQ:RPRX) to “buy” from “neutral,” with a new price target of $5.50. The stock closed at $1.93 on Wednesday.

In a new report, analyst Matthew Kaplan writes that Repros has announced positive Phase 2b data for both its oral and vaginal delivery trials, following two, 18-week cycles of treatment with Proellex for the treatment of uterine fibroids.

Read More